Background {#Sec1}
==========

Recently, combination chemotherapy of cytotoxic agents such as irinotecan, oxaliplatin, and fluorouracil, and molecular targeted-drugs, including anti-vascular endothelial growth factor antibody and anti-epidermal growth factor antibody have extended the overall survival (OS) of patients with metastatic colorectal cancer (mCRC) \[[@CR1]\]. The efficacy of fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for mCRC patients in terms of overall response rate (ORR), progression-free survival (PFS), and OS was confirmed by several studies \[[@CR2]\]. The benefit of adding bevacizumab (Bev) to the FOLFOXIRI regimen has also been demonstrated and the use of FOLFOXIRI plus Bev as an upfront treatment for mCRC patients is currently widely used \[[@CR3], [@CR4]\]. In the Pan-Asian adopted European Society for Medical Oncology (ESMO) consensuses guidelines, FOLFOXIRI plus Bev is recommended as first-line cytoreduction chemotherapy in "fit" mCRC patients with right-sided primary tumor location or for those with the *BRAF* V600E mutation \[[@CR5]\]. FOLFOXIRI plus Bev is also one of the alternative treatment options of first-line chemotherapy of mCRC listed in several treatment guidelines, including the Japanese Society for Cancer of the Colon and Rectum Guidelines 2019 \[[@CR6]\]. Furthermore, the MEBGEN RASKET™-B kit was recently approved in Japan for detecting mCRC patients with the *BRAF* V600E mutation \[[@CR7]\]. Therefore, it is expected that the number of patients treated with FOLFOXIRI plus Bev will increase.

With regard to adverse events of FOLFOXIRI plus Bev, grade 3 or higher neutropenia or febrile neutropenia (FN) frequently occur. Several studies have shown that approximately 50% of patients experience grade 3 or higher neutropenia \[[@CR3], [@CR8]--[@CR11]\]. In a Japanese phase 2 trial of FOLFOXIRI plus Bev for mCRC, Grade 3 or higher neutropenia and FN occurred in 72.5 and 21.7%, respectively \[[@CR12]\]. The American Society of Clinical oncology practice guidelines recommend the prophylactic use of granulocyte colony stimulating factor (G-CSF) when the risk of FN in approximately 20% or higher \[[@CR13]\]. Thus, we consider prophylactic G-CSF to be suitable for Japanese patients treated with FOLFOXIRI plus Bev. However, a dose adjustment of the chemotherapy is often required, and the management of neutropenia is often inadequate, even if G-CSF is administered. Polyethylene glycol-conjugated G-CSF (PEG-G-CSF), which is characterized as having an increased circulating half-life, has the potential to shorten the duration and severity of neutropenia. However, while the addition of PEG-G-CSF with FOLFOXIRI plus Bev may be useful in preventing severe neutropenia or FN, there are currently few reports evaluating the efficacy of the PEG-G-CSF for neutropenia in mCRC patients administered FOLFOXIRI plus Bev and in the safety of PEG-G-CSF administered every 2 weeks. The current study aimed to evaluate the efficacy and safety of the PEG-G-CSF for preventing neutropenia in mCRC patients treated with FOLFOXIRI plus Bev.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients diagnosed with mCRC and that received FOLFOXIRI plus Bev between December 2015 and December 2017 at the Cancer Institute Hospital, Tokyo, Japan were included in the study based on the following eligibility criteria: 1) histologically confirmed colorectal adenocarcinoma; 2) unresectable or recurrent disease; 3) no previous chemotherapy except for adjuvant chemotherapy completed more than 6 months prior to the starting date of FOLFOXIRI plus Bev treatment. The protocol summary was described on the hospital website, and the subjects were provided with the opportunity to opt-out. Therefore, no new consent for this study was required from the patients.

Data collection {#Sec4}
---------------

All data were collected by reviewing medical records and imaging results. We confirmed the patient age, sex, and Eastern Cooperative Oncology Group Performance Status (ECOG-PS). Data regarding the primary tumor site, the histological type of primary site tumor, whether primary resection was performed, the metastatic sites, and the number of metastatic sites were also considered. Any previous adjuvant chemotherapy, the tumor maker level before chemotherapy, *RAS* and *UGT1A1* status, the number of chemotherapy cycles, tumor response (objective response and early tumor shrinkage (ETS)), toxicity, conversion surgery rate, the date of disease progression, and the date of the last follow-up were also evaluated.

Treatment and evaluation {#Sec5}
------------------------

Bev was administered as a 5 mg/kg intravenous dose. FOLFOXIRI treatment consisted of a 165 mg/m^2^ intravenous infusion of irinotecan for 60 min, followed by an 85 mg/m^2^ intravenous infusion of oxaliplatin given concurrently with 200 mg/m^2^ leucovorin for 120 min followed by a 3200 mg/m^2^ continuous infusion of fluorouracil for 48 h. The primary endpoint is the incidence of grade 3 or 4 neutropenia after administrating PEG-G-CSF. PEG-G-CSF (3.6 mg) starting at day four was administered every 2 weeks until progression. Whether PEG-G-CSF was used as a primary preventative treatment for neutropenia or as a secondary treatment after a patient experienced grade 4 neutropenia or FN was decided by the treating physician. In addition, the overall tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. PFS was measured as the day of initiation of FOLFOXIRI plus Bev therapy to the day on which disease progression was confirmed or to the final day of follow-up without disease progression. OS was measured as the day of initiation of FOLFOXIRI plus Bev therapy until the final day of follow-up. ETS was defined as the relative change in the sum of the longest diameters at week eight (± 4 weeks) compared to that of the baseline (cutoff: 20%).

Statistical analysis {#Sec6}
--------------------

PFS and OS rates were estimated using the Kaplan-Meier method. All statistical analyses were performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

The demographics and clinical characteristics of the 26 patients before the initiation of FOLFOXIRI plus Bev therapy are summarized in Table [1](#Tab1){ref-type="table"}. Out of the 26 patients, 20 (77.0%) received PEG-G-CSF. Eleven patients received it secondarily to treat neutropenia. Among these 11 patients, 2 had previously been treated prophylactically with conventional G-CSF. Nine patients were administrated PEG-G-CSF prophylactically (Fig. [1](#Fig1){ref-type="fig"}). The median follow-up period was 24.2 months (range, 13.6-NA). The median age of the patients was 53.5 years (range, 27--74 years). Thirteen patients (50.0%) were male and 18 patients (69.2%) had an ECOG-PS of 0. The primary location of colorectal cancer was on the right side for eight (30.8%) of the patients. In addition, in the prophylactic PEG-G-CSF group, the right-sided primary tumor location was more frequent than those in the non-prophylactic PEG-G-CSF group (55.6% vs. 9.0% *P* \< 0.05). The histology type was either poorly differentiated or mucinous adenocarcinoma in 5 patients (19.3%) and the primary lesion was resected in eight patients (30.8%). Metastatic lesions of the liver, lung, lymph nodes and peritoneum were detected in 23 (88.4%), 7 (26.9%), 16 (61.5%), and 5 (19.3%) of the patients, respectively. Twenty-one patients (80.7%) had two or more metastatic sites. The median carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19--9) levels before chemotherapy were 88.0 ng/ml (range, 1.5--9205) and 75.4 IU/ml (range, \< 2--50,000), respectively. Twenty-three patients (88.5%) had *RAS* mutation and *UGT1A1* polymorphism was observed in eight patients (30.7%). Table 1Patient demographics and clinical characteristicsCharacteristicsTotal (***n*** = 26) No. of patients (%)With Prophylactic PEG-G-CSF (***n*** = 9)Without Prophylactic PEG-G-CSF (***n*** = 11)No use of PEG-G-CSF (***n*** = 6)**Age at enrollment, years** Median53.5515840.5 Range27--7434--7427--6735--57**Gender** Male13 (50.0)6 (66.7)3 (27.2)4 (66.7) Female13 (50.0)3 (33.3)8 (72.3)2 (33.3)**ECOG-PS** /018 (69.2)8 (88.9)7 (63.6)3 (50.0) /18 (30.8)1 (11.1)4 (36.4)3 (50.0)**Primary location** Right8 (30.8)5 (55.6)1 (9.0)2 (33.3) Left18 (69.2)4 (44.4)10 (91.0)4 (66.7)**Histology** Diffuse5 (19.3)1 (11.1)3 (27.2)1 (16.7) Intestinal21 (80.7)8 (88.9)8 (72.3)5 (83.3)**Primary resection before chemotherapy** Yes8 (30.8)3 (33.3)4 (36.4)1 (16.7) No18 (69.2)6 (66.7)7 (63.6)5 (83.3)**Diagnosis of metastasis** Metachronous5 (19.3)3 (33.3)2 (18.2)0 (0) Synchronous21 (80.7)6 (66.7)9 (81.8)6 (100)**Metastatic site** Liver23 (88.4)8 (88.9)9 (81.8)6 (100) Lung7 (26.9)3 (33.3)4 (36.4)0 (0) Lymph node16 (61.5)2 (22.2)8 (72.3)6 (100) Peritoneum5 (19.3)0 (0)4 (36.4)1 (16.7) Other3 (11.5)2 (22.2)1 (9.0)0 (0)**Number of metastatic sites** 14 (15.4)2 (22.2)2 (18.2)0 (0)  ≥ 222 (84.6)7 (77.8)9 (81.8)6 (100)**Previous adjuvant chemotherapy** Yes2 (7.7)1 (11.1)1 (9.0)0 (0) No24 (92.3)8 (88.9)10 (91.0)6 (100)**RAS status** Wild type3 (11.5)0 (0)2 (18.2)1 (16.7) Mutant type23 (88.5)9 (100)9 (81.8)5 (83.3)**UGT1A1 Status** Wild type7 (26.9)3 (33.3)3 (27.2)1 (16.7) \*66 (23.0)2 (22.2)2 (18.2)2 (33.3) \*282 (7.7)0 (0)2 (18.2)0 (0) Unknown11 (42.4)4 (44.5)4 (36.4)3 (50.0)**CEA median, \[range\]**88.0 \[1.5--9205\]12.2 \[4.6--5638\]155.9 \[5--25,873\]155.9 \[5--25,873\]**CA19--9 median, \[range\]**75.4 \[2--50,000\]99.7 \[5.9--50,000\]40.2 \[2.7--982\]40.2 \[2.7--982\]Fig. 1Frequency and reasons for the use of polyethylene glycol-conjugated granulocyte colony-stimulating factor (PEG-G-CSF)

**Abbreviations:** ECOG PS, eastern cooperative oncology group performance status; CEA, carcinoembryonic antigen; CA19--9, carbohydrate antigen 19--9; FN: febrile neutropenia; PEG-G-CSF: polyethylene glycol-conjugated granulocyte colony stimulating factor

Adverse events, efficacy, and safety of PEG-GCSF in mCRC patients treated with FOLFOXIRI plus Bev {#Sec9}
-------------------------------------------------------------------------------------------------

Grade3 or 4 toxicities of FOLFOXIRI plus Bev were shown in Table [2](#Tab2){ref-type="table"}. The most common adverse event was hematological toxicity with grade 3 or 4 neutropenia, which was observed in 14 patients (53.8%). Grade 3 FN was observed in two patients (7.7%). Other hematological or non-hematological toxicities were less frequent such as diarrhea being observed in two patients (7.7%). No treatment-related deaths occurred. Of the 26 patients, 20 (77%) received PEG-G-CSF. None of the patients developed grade 3 or 4 neutropenia after receiving PEG-G-CSF. Ten of the 26 patients (38.5%) received a reduction in their dose of FOLFOXIRI plus Bev. Six of the 11 patients (54.6%) who received PEG-G-CSF secondarily to treat neutropenia were able to continue treating with FOLFOXIRI plus Bev without the need for a dose adjustment. On the other hand, in the 9 patients given PEG-G-CSF prophylactically, 2 (22.2%) required the dose adjustment due to non-hematological adverse events. There were no severe adverse events associated with PEG-G-CSF treatment. Table 2Toxicities according to CTCAE, version 4.0 (grade 3 or higher)CharacteristicsTotal (***n*** = 26)\
No. of patients (%)**Hematotoxicity** Neutropenia14 (53.8) Febrile neutropenia2 (7.7) Anemia1 (3.8)**Nonhematotoxicity** Infection2 (7.7) Nausea1 (3.8) Fatigue1 (3.8) Diarrhea2 (7.7) Spinal infarction1 (3.8) Renal dysfunction1 (3.8) Hypertension1 (3.8) Perforation2 (7.7)

Treatment outcomes {#Sec10}
------------------

Treatment outcomes was shown in Table [3](#Tab3){ref-type="table"}, respectively. The median number of treatment cycles per patient was 6.5 (range, 1.0--14.0). The ORR was 65.3% (95% confidence interval \[CI\], 44.0--83.0) and the disease control rate was 84.5% (95% CI, 65.0--96.0). PFS and OS were 9.6 months (95% CI, 7.2--16.9) and 24.2 months (95% CI, 13.6--NA), respectively (Fig. [2](#Fig2){ref-type="fig"}). Thirteen patients (50.0%) were identified as demonstrating early tumor shrinkage, and seven patients (26.9%) received conversion surgery. As for the outcome of the patients using PEG-G-CSF, the PFSs were 4.9 and 16.9 months for the prophylactic and secondary groups, respectively (*p* \< 0.05). Table 3Chemotherapeutic EfficacyCharacteristicsTotal (***n*** = 26) No. of patients (%)With Prophylactic PEG-G-CSF (***n*** = 9)Without Prophylactic PEG-G-CSF (***n*** = 11)No use of PEG-G-CSF (***n*** = 6)**Number of cycles** Median6.5867 Range1.0--14.03.0--10.05.0--14.01.0--11.0**Dose reduction** Yes10 (38.5)2 (22.2)5 (45.4)3 (50.0) No16 (61.5)7 (77.8)6 (54.6)3 (50.0)**ORR** Partial response17 (65.3)3 (33.3)10 (90.9)4 (66.7) Stable disease5 (19.2)2 (22.3)1 (9.1)2 (33.3) Progressive disease1 (3.8)1 (11.1)0 (0)0 (0) Not evaluate3 (11.5)3 (33.3)0 (0)0 (0)**Conversion surgery** Yes7 (26.9)2 (22.2)5 (45.4)2 (33.3) No19 (73.1)7 (77.8)6 (54.6)4 (66.7)**Early Tumor Response** Yes13 (50.0)1 (11.1)9 (81.8)3 (50.0) No10 (38.4)5 (55.6)2 (18.2)3 (50.0) Not evaluated3 (11.6)3 (33.3)0 (0)0 (0)Fig. 2Progression-free survival and overall survival rates of the study cohort

Discussion {#Sec11}
==========

In the current study, we evaluated the efficacy and safety of the PEG-G-CSF for preventing neutropenia in mCRC patients treated with FOLFOXIRI plus Bev. PEG-G-CSF prevented the development of severe neutropenia without any increases of adverse events. FN is one of the life-threatening adverse events of chemotherapy. In the 1990s, G-CSF was widely used in the clinic as a leading supportive therapy for FN. There is substantial data regarding the effectiveness of G-CSF for cancer chemotherapy \[[@CR14], [@CR15]\]. Compared to conventional G-CSF, the number of visits to a hospital by patients and the workload of the medical staff both decreased when we used PEG-G-CSF. This demonstrates a great benefit for the outpatient clinic.

There are several reports regarding the efficacy of PEG-G-CSF for neutropenia and FN in both mCRC and other cancers, as shown in Table [4](#Tab4){ref-type="table"}. A Japanese double-blind placebo-controlled randomized phase 3 trial of PEG-G-CSF in 343 breast cancer patients receiving docetaxel and cyclophosphamide chemotherapy showed that the incidence of FN was significantly lower in the PEG-G-CSF group compared to that in the placebo group (1.2% vs. 68.8%, *P \<* 0.001) \[[@CR24]\]. Regarding mCRC patients, in a phase 3 double-blind trial that evaluated the efficacy of PEG-G-CSF compared to a placebo in reducing the incidence of grade 3 or 4 FN in patients with advanced CRC receiving Bev combined with first-line chemotherapy, PEG-G-CSF significantly reduced the incidence of grade 3 or 4 FN in the first four treatment cycles (PEG-G-CSF 2.4%, placebo, 5.7%, *P* = 0.014) \[[@CR18]\]. Another randomized placebo-controlled phase 2 study examined PEG-G-CSF efficacy and safety in patients with CRC that received chemotherapy every 2 weeks. Results from this study showed that PEG-G-CSF significantly reduces the incidence of grade 3 or 4 FN (PEG-G-CSF, 2.0%; placebo, 8.0%; *P* \< 0.001) \[[@CR28]\]. Notably, this study demonstrated that PEG-G-CSF could prevent severe neutropenia in patients receiving FOLFOXIRI plus Bev on a two-week cycle without an increase of adverse events, consistent with previous reports. However, the safety of PEG-G-CSF had not been established when administered within 14 days before the start of chemotherapy. It is recommended that the administration interval of PEG-G-CSF should be 2 weeks or longer. Table 4Previous reports of efficacy of PEG-G-CSFNo.AuthorYearPrimary TumorRegimenPatients numberMajor outcomes1Yamao et al. \[[@CR16]\]2019PCmFOLFIRINOX45PFS (prolonged)2Xie et al. \[[@CR17]\]2018BCEC, TC, ET569Incidence and duration of grade 3/4 neutropenia3Pinter et al. \[[@CR18]\]2017CRCFOLFOX, FOLFIRI845Incidence of grade 3/4 FN in the first 4 cycles4Kubo et al. \[[@CR19]\]2016MLCHASE(R)111Duration of severe neutropenia5Lee et al. \[[@CR20]\]2016BCTAC60Duration of grade 4 neutropenia in cycle 16Blackwell et al. \[[@CR21]\]2016BCTAC308Duration of severe neutropenia during cycle 17Harbeck et al. \[[@CR22]\]2016BCTAC316Duration of severe neutropenia during cycle 18Zhang et al. \[[@CR23]\]2015BCTAC171Incidence of grade 3/4 neutropenia9Kosaka et al. \[[@CR24]\]2015BCTC351Incidence of FN10Bozzoli et al. \[[@CR25]\]2015DLBCLRCHOP51Frequency of FN and unplanned hospitalizations11Gladkov et al. \[[@CR26]\]2015BCDoxorubicin/Docetaxel78Incidence of adverse events12Shi et al. \[[@CR27]\]2013BC, NSCLC, NHL, HNCPC, AC, CHOP337Rate of protection against grade 4 neutropenia13Hecht et al. \[[@CR28]\]2010CRCFOLFOX, FOLFIRI, FOIL241Incidence of grade 3/4 neutropenia.14Fox et al. \[[@CR29]\]2009SarcomaVDC, IE34Duration of severe neutropenia15Sierra et al. \[[@CR30]\]2008AMLIdarubicin/cytarabine84Assisting neutrophil recovery16von Minckwitz et al. \[[@CR31]\]2008BCTAC1256Primary prophylaxis of FN and related toxic effects17Bladucci et al. \[[@CR32]\]2007Solid tumors or NHLCarboplatin, Cisplatin, Doxorubicin, Doxorubicin and Paclitaxel, AC, Docetaxel, ACT, FEC, CHOP, EPOCH, Topotecan852Proportion of patients experiencing FN18Romieu et al. \[[@CR33]\]2007BCFEC60Incidence of neutropenic events19Vogel et al. \[[@CR34]\]2005BCDocetaxel928Percentage of patients developing FN20Grigg et al. \[[@CR35]\]2003NHLCHOP50Duration of grade 4 neutropenia21Vose et al. \[[@CR36]\]2003MLESHAP66Incidence of grade 4 FN22Green et al. \[[@CR37]\]2003BCDA157Incidence of Grade 4 neutropenia23Holmes et al. \[[@CR38]\]2002BCDA310Absolute neutrophil count24Holmes et al. \[[@CR39]\]2002BCDA154Incidence of Grade 4 neutropenia in cycle 125Johnston et al. \[[@CR40]\]2000NSCLCCarboplatin and Paclitaxel13Serum concentrations

In addition, *UGT1A1* polymorphism was detected in this study in eight (30.7%) of the patients (\*6 in six patients, \*28 in two patients). Among these patients with *UGT1A1* polymorphism, six had been administered PEG-G-CSF, two after the development of grade 3 neutropenia, and four prophylactically. In Japan, the incidence of *UGT1A1* \*6 polymorphism is higher than that in the US and European countries \[[@CR41]--[@CR43]\]. In a Japanese phase 2 trial of FOLFOXIRI plus Bev in mCRC patients, the frequency of neutropenia in patients with *UGT1A1* \*6 or \*28 polymorphism is higher than that in patients with wild-type *UGT1A1*^10^. However, in the current study, no patients experienced severe neutropenia after the administration of PEG-G-CSF, even those with *UGT1A1* \*6 or \*28 polymorphism. Furthermore, 5 of the 6 patients could continue the FOLFOXIRI plus Bev treatment without any need for a dose adjustment. These data suggest that the administration of PEG-G-CSF with a two-week cycle may be safe and PEG-G-CSF can prevent severe neutropenia in patients with *UGT1A1* \*6 or \*28 polymorphism.

There were several limitations of our study. Firstly, this was a retrospective study with relatively small sample size. Secondly, PFS was significantly different between the prophylactic and non-prophylactic PEG-G-CSF groups. This difference was partially because the mCRC patients in the prophylactic PEG-G-CSF group mostly had the tumor on the right side, rather than the left, and this sub-group has poorer survival than the patients with the tumor on the left. Therefore, further research is necessary to evaluate the correlation between the timing of PEG-G-CSF use (prophylactic or non-prophylactic) and survival. However, even with these limitations, the results of this study showed that neutropenia, which is the most common adverse event in patients under treatment with FOLFOXIRI plus Bev, could be prevented by using PEG-G-CSF.

**Abbreviations:** PC, pancreatic cancer; BC, breast cancer; CRC, colorectal cancer; ML, malignant lymphoma; DLBCL, diffuse large B-cell lymphoma; NSCLC, non-small cell lung carcinoma; NHL, non-Hodgkin's lymphoma; HNC, head and neck carcinoma; AML, acute myeloid leukemia; mFOLFIRINOX, modified fluorouracil, leucovorin, oxaliplatin, and irinotecan: EC, epirubicin and cyclophosphamide; TC, Taxotere and cyclophosphamide; ET, endocrine therapy; CHASE(R), cyclophosphamide, cytarabine, dexamethasone, etoposide (and rituximab); DA,; TAC, taxotate, adriamycin and cyclophosphamide, (R) CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; PC, paclitaxel and carboplatin; AC, adriamycin and cyclophosphamide; VDC, vincristine, doxorubicin and cyclophosphamide; IE, fosfamide and etoposide; ACT, doxorubicin, cyclophosphamide and docetaxel; FEC, falmorubicin, endoxane and 5-fluorouracil; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin; ESHAP, prednisolone, etoposide, cytarabine and cisplatin; DA, docetaxel and doxorubicin;

Conclusion {#Sec12}
==========

PEG-G-CSF is useful for both primary and secondary prevention of severe neutropenia in mCRC patients treated with FOLFOXIRI plus Bev without increases in adverse events.

PEG-G-CSF

:   Polyethylene glycol conjugated granulocyte colony-stimulating factor

mCRC

:   Metastatic colorectal cancer

FOLFOXIRI

:   Fluorouracil, leucovorin, oxaliplatin, and irinotecan

Bev

:   Bevacizumab

ORR

:   Overall response rate

PFS

:   Progression-free survival

OS

:   Overall survival

ESMO

:   European Society for Medical Oncology

FN

:   Febrile neutropenia

ECOG-PS

:   Eastern Cooperative Oncology Group Performance Status

ETS

:   Early tumor shrinkage

RECIST

:   Response Evaluation Criteria in Solid Tumors

CTCAE

:   Common Terminology Criteria for Adverse Events

CEA

:   Carcinoembryonic antigen

CA19--9

:   Carbohydrate antigen

PC

:   Pancreatic cancer

BC

:   Breast cancer

CRC

:   Colorectal cancer

ML

:   Malignant lymphoma

DLBCL

:   Diffuse large B-cell lymphoma

NSCLC

:   Non-small cell lung carcinoma

NHL

:   Non-Hodgkin's lymphoma

HNC

:   Head and neck carcinoma

AML

:   Acute myeloid leukemia

mFOLFIRINOX

:   Modified fluorouracil, leucovorin, oxaliplatin, and irinotecan

EC

:   Epirubicin and cyclophosphamide

TC

:   Taxotere and cyclophosphamide

ET

:   Endocrine therapy

CHASE(R)

:   Cyclophosphamide, cytarabine, dexamethasone, etoposide (and rituximab)

DA

:   Docetaxel and doxorubicin

TAC

:   Taxotate, adriamycin and cyclophosphamide

(R)CHOP

:   (Rituximab), cyclophosphamide, doxorubicin, vincristine, and prednisolone

PC

:   Paclitaxel and carboplatin

AC

:   Adriamycin and cyclophosphamide

VDC

:   Vincristine, doxorubicin, and cyclophosphamide

IE

:   Fosfamide and etoposide

ACT

:   Doxorubicin, cyclophosphamide, and docetaxel

FEC

:   Falmorubicin, endoxane and 5-fluorouracil

EPOCH

:   Etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin

ESHAP

:   Prednisolone, etoposide, cytarabine and cisplatin
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